IP Library Granted Patent US 8,357,697
Granted Patent B2
US 8,357,697 · App. 13/237,709 · Granted Jan 22, 2013

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,357,697
App. No.
13/237,709
Granted
Jan 22, 2013
Kind
B2
Abstract

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol compounds are disclosed that are inhibitors of the vesicular monoamine transporter 2 (VMAT2). The compounds of this invention have the structure: wherein R 1 is as defined herein, including stereoisomers and pharmaceutically acceptable salts and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use in a subject in need thereof.

Claims (7)

1. A method of treating a hyperkinetic disorder, said method comprising administering to a subject a pharmaceutically effective amount of a pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier or diluent and (b) (S)-2-Amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester or a pharmaceutically acceptable salt or solvate thereof.

2. The method according to claim 1 wherein the hyperkinetic disorder is Huntington's disease, tardive dyskinesia, Tourette's syndrome or tics.

3. The method according to claim 1 wherein the hyperkinetic disorder is Huntington's disease.

4. The method according to claim 1 wherein the hyperkinetic disorder is tardive dyskinesia.

5. The method according to claim 1 wherein the hyperkinetic disorder is Tourette's syndrome.

6. The method according to claim 1 wherein the hyperkinetic disorder is tics.

7. A method for inhibiting monoamine transporter isoform 2 (VMAT2) in a subject comprising administering to the subject a pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier or diluent and (b) (S)-2-Amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester or a pharmaceutically acceptable salt or solvate thereof.

Assignments (3)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 26, 2026
From: NEUROCRINE BIOSCIENCES, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 075670/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2023
From: GANO, KYLE W.; HARRIOTT, NICOLE
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 063716/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2019
From: GANO, KYLE W.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 048124/0753 →